Q3 2019 Targovax ASA Earnings Call Transcript
¸ -
Good morning, everyone, and welcome to the third quarter presentation of Targovax. I am Torbjørn Furuseth, the CFO of the company. And together with me today also have Ãystein Soug, our CEO.
There will be forward-looking statements today. The agenda. First, we will start with a short introduction of the company and the financials and the highlights of the quarter. And then Ãystein will take you through melanoma. We will present preclinical data on our next-generation viruses, short touch-up on the mesothelioma trial and then the upcoming news flow.
Cancer therapy has gone through a paradigm shift with the introduction of immunotherapy, and this shift has been led by the checkpoint inhibitors that have cured thousands of patients and is now a $20 billion market.
Despite this success, it's actually only 10% to 40% of the patients that are responding to their checkpoint inhibitors. And for some indications, the response rates are even lower. You could be -- you could combine some other checkpoint inhibitors, but that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
